NEW YORK (GenomeWeb News) – Sequenom said today that it has obtained exclusive rights to Genomic Nanosystems’ digital PCR technologies and techniques.
 
The agreement gives Sequenom exclusive rights to use the digital PCR methods for non-invasive, prenatal diagnostic testing and sample analysis on any platform. In addition, the company will have exclusive rights to use digital PCR in conjunction with mass spectrometry for all commercial, diagnostic, or research applications except second-generation sequencing.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.